Shape tunable plasmonic nanoparticles
View Patent ↗Noble metal nanoparticles and methods of their use are provided. Certain aspects provided solid noble metal nanoparticles tuned to the near infrared. The disclosed nanoparticles can be used in molecular imaging, diagnosis, and treatment. Methods for imaging cells are also provided.
1. A method for killing cancer cells in a subject in need thereof, comprising:
a. administering to the subject one or more solid noble metal nanorods coupled to a binding moiety that specifically binds to a target substance expressed by cancer cells to a region of the subject, wherein the solid noble metal nanorods consist essentially of gold or silver metal having an aspect ratio of about 2.7 to about 10; and
b. exposing the one or more solid noble metal nanorods to near infra-red light from a continuous wave laser at a density of at least 9 W/cm 2 and less than 18 W/cm 2 ; wherein the one or more solid noble metal nanorods absorbs the light and converts the absorbed light to heat, and wherein the heat kills the cancer cells.
2. The method of claim 1 , wherein the region is within about 5 mm of an exterior surface of the host.
3. The method of claim 1 , wherein the target substance is selected from the group consisting of epidermal growth factor receptor, transferrin receptor, platelet-derived growth factor receptor, Erb-B2, CD 19, CD20, CD45, CD52, Ep-CAM, alpha ([alpha])-fetoprotein, carcinoembryonic antigen peptide-1, caspase-8, CDC27, CDK4, carcino-embryonic antigen, calcium-activated chloride channel-2, cyclophilin B, differentiation antigen melanoma, elongation factor 2, Ephrin type-A receptor 2, 3, Fibroblast growth factor-5, fibronectin, glycoprotein 250, G antigen, N-acetylglucosaminyltransferase V, glycoprotein 100 kD, helicase antigen, human epidermal receptor-2/neurological, heat shock protein 70-2 mutated, human signet ring tumor-2, human telomerase reverse transcriptase, intestinal carboxyl esterase, interleukin 13 receptor [alpha]2 chain, [beta]-D-galactosidase 2-[alpha]-L-fucosyltransferase, melanoma antigen, melanoma antigen recognized by T cells-1/Melanoma antigen A, melanocortin 1 receptor, macrophage colony-stimulating factor, mucin 1, 2, melanoma ubiquitous mutated 1, 2, 3, New York-esophageous 1, ocular albinism type 1 protein, O-linked N-acetyl glucosamine transferase gene, protein 15, promyelocytic leukemia/retinoic acid receptor [alpha], prostate-specific antigen, prostate-specific membrane antigen, receptor-type protein-tyrosinephosphatase kappa, renal antigen, renal ubiquitous 1, 2, sarcoma antigen, squamous antigen rejecting tumor 1, 2, 3, synovial sarcoma, Survivin-2B, synaptotagmin I/synovial sarcoma, X fusion protein, translocation Ets-family leukemia/acute myeloid leukemia 1, transforming growth factor [beta] receptor 2, triosephosphate isomerase, taxol resistant associated protein 3, testin-related gene, tyrosinase related protein 1, and tyrosinase related protein 2.
4. A method for killing cancer cells in a subject in need thereof comprising:
administering a plurality of solid gold metal nanorods consisting of gold metal having an aspect ratio of about 2.7 to about 10 and having a surface plasmon resonance absorption maximum greater than about 600 nm wherein the solid gold metal nanorods are targeted to one or more cancer cells and specifically associate with one or more cancer cells; and
exposing the plurality of gold metal nanorods with near infra-red light at a density of at least 9 W/cm 2 and less than 18 W/cm 2 using a continuous wave laser to generate an amount of heat from the gold metal nanorods effective to kill the targeted cancer cells associated with the solid gold metal nanorods.
5. The method of claim 4 , wherein the solid gold metal nanorods are targeted to cancer cells via one or more binding moieties conjugated to the solid gold metal nanorods.
6. The method of claim 4 , wherein the solid gold metal nanorods are targeted to the cancer cells via a polymeric coating.
7. The method of claim 6 , wherein the polymeric coating comprises polyethylene glycol.
8. The method of claim 1 , wherein the near-infrared light has a wavelength of 800 nm.
9. The method of claim 4 , wherein the near-infrared light has a wavelength of 800 nm.
10. The method of claim 8 , wherein the nanorods are 50 nm in length and 15 nm in width.
11. The method of claim 9 , wherein the nanorods are 50 nm in length and 15 nm in width.
12. The method of claim 4 wherein the amount of light effective to kill the cancer cells is about 5 to about 80% of the amount of light needed to damage non-cancerous cells.